1. Class action lawsuit filed against Replimune for securities violations. 2. Allegations include false statements about IGNYTE trial outcomes. 3. Investors from Nov 2024 to Jul 2025 can join the lawsuit. 4. Schall Law Firm represents shareholders in this case. 5. Class hasn't been certified, thus no attorney representation yet.
The lawsuit and allegations of misinformation may lead to loss of investor trust and stock price decline, similar to cases in the past such as Valeant Pharmaceuticals' significant market drop following legal issues. Historical cases illustrate a pattern where stock value depreciates amid fraud allegations resulting in a class action.
The relevance of the class action lawsuit directly challenges REPL's credibility and could significantly affect its market valuation. Major legal challenges often precede further stock depreciation if unresolved, solidifying the impact.
Immediate sentiment will likely deteriorate as investors react to potential instability. Quick resolution scenarios often lead to volatility in similarly affected stocks.
LOS ANGELES, Aug. 18, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between November 22, 2024 and July 21, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before September 22, 2025.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Replimune overstated the prospects of its IGNYTE trial for RP1 (vusolimogene oderparepvec). The Company knew or should have known of material issues with the trial that would result in the FDA finding it was inadequate and poorly controlled. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Replimune, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/repl-investors-have-opportunity-to-lead-replimune-group-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302531878.html
SOURCE The Schall Law Firm